As molecular imaging transitions from undercard modality to mainstream tool in diagnostic imaging, the reality of personalized healthcare appears to be on the horizon. An increasing limelight placed on the modality has attracted both investors and new companies, leading to significant milestones in R&D and thus fulfilling the promise of “true” personalized medicine.

While the DRA has cut short the burgeoning growth of imaging services, particularly those offered by outpatient centers, it also presents other players in the imaging value chain with new opportunities.